Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world. This year’s winners are working on solutions including AI transparency, climate risk, virus modeling, and more.

CB Insights has unveiled the winners of the fifth annual AI 100. This year’s cohort of promising private AI companies represents 12 countries and is driving innovation across 18 industries and a broad range of cross-industry applications.

The products that this year’s winners are bringing to market — from drug R&D and revenue cycle management for hospitals to autonomous beekeeping and municipal waste sortation — highlight the breadth and depth of AI’s impact on industries.

Using the CB Insights platform, our research team picked these 100 private market vendors from a pool of over 6K companies, including applicants and nominees. They were chosen based on factors including business relations, investor profile, news sentiment analysis, R&D activity, proprietary Mosaic scores, market potential, competitive landscape, team strength, and tech novelty.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Blog

Success is never a straight line—reflecting on our EMA draft qualification opinion

On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.